# AUTX-703

Source: https://onco.cc/drugs/autx-703/  
OnCo record `autx-703` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AUTX-703 is an experimental small-molecule protein degrader from Auron Therapeutics, in phase 1 trials for acute myeloid leukaemia, myelodysplastic syndrome and small cell lung cancer and other cancers.

## Summary

AUTX-703 is a small-molecule protein degrader (oral) from Auron Therapeutics. A first-in-class oral degrader of the lysine acetyltransferases KAT2A and KAT2B, which the company says epigenetically reprogram cells to a more proliferative and plastic state. Its furthest stage is phase 1, for acute myeloid leukaemia, myelodysplastic syndrome, small cell lung cancer and neuroendocrine prostate cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT06846606 recruiting (registry, 3 Nov 2026). FDA Fast Track for r/r AML per company page. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: AUTX-703
- Modality: Small-molecule protein degrader (oral)
- Mechanism: A first-in-class oral degrader of the lysine acetyltransferases KAT2A and KAT2B, which the company says epigenetically reprogram cells to a more proliferative and plastic state.

## Sources

- Auron Therapeutics: aurontx.com: https://aurontx.com/programs-and-pipeline
- Auron Therapeutics: aurontx.com: https://aurontx.com/programs-and-pipeline
- Auron Therapeutics: aurontx.com: https://aurontx.com/programs-and-pipeline
- Auron Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06846606
- ClinicalTrials.gov: trials of AUTX-703: https://clinicaltrials.gov/search?intr=AUTX-703

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- targets: [KAT2A](https://onco.cc/targets/kat2a/), [KAT2B](https://onco.cc/targets/kat2b/)
- companies: [Auron Therapeutics](https://onco.cc/companies/auron-therapeutics/)
- trials: [Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS](https://onco.cc/trials/nct06846606/)

---
JSON: https://onco.cc/api/v1/entities/autx-703.json